{"type":"Disease","keywords":[],"name":"D-Glyceric aciduria","alternate_names":[],"attribute_content":[],"alternate_symbols":[],"medgen_id":"C0342765","xrefs":[],"id":"39924"}
{"type":"Disease","keywords":[],"name":"Neutrophil immunodeficiency syndrome","alternate_names":["IMMUNODEFICIENCY 73A WITH DEFECTIVE NEUTROPHIL CHEMOTAXIS AND LEUKOCYTOSIS"],"attribute_content":[],"alternate_symbols":[],"medgen_id":"C1842398","symbol":"IMD73A","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011988\"}","{\"db\":\"OMIM\",\"id\":\"608203\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"183707\"}","{\"db\":\"OMIM\",\"id\":\"602049.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 73A WITH DEFECTIVE NEUTROPHIL CHEMOTAXIS AND LEUKOCYTOSIS\"}","{\"db\":\"OMIM\",\"id\":\"608203\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"IMMUNODEFICIENCY 73A WITH DEFECTIVE NEUTROPHIL CHEMOTAXIS AND LEUKOCYTOSIS\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Neutrophil+immunodeficiency+syndrome/9007\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"608203\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"5642"}
{"type":"Disease","gard_id":"12395","keywords":[],"name":"Congenital disorder of glycosylation type 1O","alternate_names":["CDG Io","CDG1(DPM3)","CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Io","MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 15","MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY, LIMB-GIRDLE, DPM3-RELATED"],"attribute_content":[],"alternate_symbols":["CDG1O","CDGIo","DPM3-CDG (CDG-Io)"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301507\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1332\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C2752007","symbol":"MDDGC15","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0013049\"}","{\"db\":\"OMIM\",\"id\":\"612937\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"263494\"}","{\"db\":\"OMIM\",\"id\":\"612937\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CDG Io\"}","{\"db\":\"OMIM\",\"id\":\"612937\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CDG1(DPM3)\"}","{\"db\":\"OMIM\",\"id\":\"612937\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"CONGENITAL DISORDER OF GLYCOSYLATION, TYPE Io\"}","{\"db\":\"OMIM\",\"id\":\"605951.0001\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 15\"}","{\"db\":\"OMIM\",\"id\":\"605951.0002\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 15\"}","{\"db\":\"OMIM\",\"id\":\"605951.0005\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 15\"}","{\"db\":\"OMIM\",\"id\":\"612937\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (LIMB-GIRDLE), TYPE C, 15\"}","{\"db\":\"OMIM\",\"id\":\"612937\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY, LIMB-GIRDLE, DPM3-RELATED\"}","{\"db\":\"OMIM\",\"id\":\"612937\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CDG1O\"}","{\"db\":\"OMIM\",\"id\":\"612937\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"CDGIo\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"12395\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"CONGENITAL+DISORDER+OF+GLYCOSYLATION%2C+TYPE+Io/8062\",\"ref_field\":\"name\"}","{\"db\":\"OMIM\",\"id\":\"612937\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"6714"}
{"type":"Disease","gard_id":"10205","keywords":[],"alternate_names":["Bardet-Biedl syndrome 6"],"attribute_content":[],"alternate_symbols":[],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301537\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1363\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGentest, 2010\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"3061994\",\"@Source\":\"pmc\"}}]}","medgen_id":"C1858054","symbol":"BBS6","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0011523\"}","{\"db\":\"OMIM\",\"id\":\"605231\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"110\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Bardet-Biedl+Syndrome+6/732\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Bardet-Biedl syndrome 6\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"10205\",\"ref_field\":\"gard_id\"}","{\"db\":\"OMIM\",\"id\":\"605231\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"8918"}
{"type":"Disease","public_definition":"X-linked sideroblastic anemia and ataxia is a rare condition characterized by a blood disorder called sideroblastic anemia and movement problems known as ataxia. This condition occurs only in males.Sideroblastic anemia results when developing red blood cells called erythroblasts do not make enough hemoglobin, which is the protein that carries oxygen in the blood. People with X-linked sideroblastic anemia and ataxia have mature red blood cells that are smaller than normal (microcytic) and appear pale (hypochromic) because of the shortage of hemoglobin. This disorder also leads to an abnormal accumulation of iron in red blood cells. The iron-loaded erythroblasts, which are present in bone marrow, are called ring sideroblasts. These abnormal cells give the condition its name. Unlike other forms of sideroblastic anemia, X-linked sideroblastic anemia and ataxia does not cause a potentially dangerous buildup of iron in the body. The anemia is typically mild and usually does not cause any symptoms.X-linked sideroblastic anemia and ataxia causes problems with balance and coordination that appear early in life. The ataxia primarily affects the trunk, making it difficult to sit, stand, and walk unassisted. In addition to ataxia, people with this condition often have trouble coordinating movements that involve judging distance or scale (dysmetria) and find it difficult to make rapid, alternating movements (dysdiadochokinesis). Mild speech difficulties (dysarthria), tremor, and abnormal eye movements have also been reported in some affected individuals.","gard_id":"668","keywords":[],"name":"X-linked sideroblastic anemia with ataxia","alternate_names":["Anemia sideroblastic and spinocerebellar ataxia","Pagon Bird Detter syndrome","Sideroblastic anemia with spinocerebellar ataxia","X-Linked Sideroblastic Anemia and Ataxia"],"attribute_content":[],"alternate_symbols":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301496\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1321\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C1845028","symbol":"ASAT","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0010524\"}","{\"db\":\"OMIM\",\"id\":\"301310\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"2802\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Anemia+Sideroblastic+and+Spinocerebellar+Ataxia/444\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Anemia sideroblastic and spinocerebellar ataxia\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1321\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"X-Linked Sideroblastic Anemia and Ataxia\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"668\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010524\",\"ref_field\":\"name\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"x-linked-sideroblastic-anemia-and-ataxia\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"301310\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"246"}
{"type":"Disease","public_definition":"Individuals with hereditary distal renal tubular acidosis (dRTA) typically present in infancy with failure to thrive, although later presentations can occur, especially in individuals with autosomal dominant SLC4A1-dRTA. Initial clinical manifestations can also include emesis, polyuria, polydipsia, constipation, diarrhea, decreased appetite, and episodes of dehydration. Electrolyte manifestations include hyperchloremic non-anion gap metabolic acidosis and hypokalemia. Renal complications of dRTA include nephrocalcinosis, nephrolithiasis, medullary cysts, and impaired renal function. Additional manifestations include bone demineralization (rickets, osteomalacia), growth deficiency, sensorineural hearing loss (in ATP6V0A4-, ATP6V1B1-, and FOXI1-dRTA), and hereditary hemolytic anemia (in some individuals with SLC4A1-dRTA).","gard_id":"4668","keywords":[],"name":"Autosomal dominant distal renal tubular acidosis","alternate_names":["RENAL TUBULAR ACIDOSIS, DISTAL, 1, AUTOSOMAL DOMINANT","RTA, classic type","RTA, distal type, autosomal dominant","RTA, gradient type","Renal Tubular Acidosis, Type I","Renal tubular acidosis 1"],"attribute_content":[],"alternate_symbols":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"31600044\",\"@Source\":\"PubMed\"},{\"$\":\"NBK547595\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C0259810","symbol":"DRTA1","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008368\"}","{\"db\":\"OMIM\",\"id\":\"179800\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"93608\"}","{\"db\":\"OMIM\",\"id\":\"109270.0012\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RENAL TUBULAR ACIDOSIS, DISTAL, 1, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"109270.0014\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RENAL TUBULAR ACIDOSIS, DISTAL, 1, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"109270.0025\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RENAL TUBULAR ACIDOSIS, DISTAL, 1, AUTOSOMAL DOMINANT\"}","{\"db\":\"OMIM\",\"id\":\"179800\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RENAL TUBULAR ACIDOSIS, DISTAL, 1, AUTOSOMAL DOMINANT\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4668\",\"ref_field\":\"gard_id\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0008368\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK547595\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"179800\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"5855"}
{"type":"Disease","public_definition":"Individuals with hereditary distal renal tubular acidosis (dRTA) typically present in infancy with failure to thrive, although later presentations can occur, especially in individuals with autosomal dominant SLC4A1-dRTA. Initial clinical manifestations can also include emesis, polyuria, polydipsia, constipation, diarrhea, decreased appetite, and episodes of dehydration. Electrolyte manifestations include hyperchloremic non-anion gap metabolic acidosis and hypokalemia. Renal complications of dRTA include nephrocalcinosis, nephrolithiasis, medullary cysts, and impaired renal function. Additional manifestations include bone demineralization (rickets, osteomalacia), growth deficiency, sensorineural hearing loss (in ATP6V0A4-, ATP6V1B1-, and FOXI1-dRTA), and hereditary hemolytic anemia (in some individuals with SLC4A1-dRTA).","gard_id":"4666","keywords":[],"name":"Renal tubular acidosis with progressive nerve deafness","alternate_names":["Distal Renal Tubular Acidosis with Progressive Sensorineural Deafness","RENAL TUBULAR ACIDOSIS, AUTOSOMAL RECESSIVE, WITH PROGRESSIVE NERVE DEAFNESS","RENAL TUBULAR ACIDOSIS, DISTAL, 2, WITH PROGRESSIVE NERVE DEAFNESS","RTA WITH PROGRESSIVE NERVE DEAFNESS"],"attribute_content":[],"alternate_symbols":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"31600044\",\"@Source\":\"PubMed\"},{\"$\":\"NBK547595\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C0403554","symbol":"DRTA2","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0009968\"}","{\"db\":\"OMIM\",\"id\":\"267300\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"93611\"}","{\"db\":\"OMIM\",\"id\":\"267300\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RENAL TUBULAR ACIDOSIS, AUTOSOMAL RECESSIVE, WITH PROGRESSIVE NERVE DEAFNESS\"}","{\"db\":\"OMIM\",\"id\":\"267300\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RENAL TUBULAR ACIDOSIS, DISTAL, 2, WITH PROGRESSIVE NERVE DEAFNESS\"}","{\"db\":\"OMIM\",\"id\":\"267300\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RTA WITH PROGRESSIVE NERVE DEAFNESS\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"4666\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Renal+tubular+acidosis+progressive+nerve+deafness/6212\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"236532003\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK547595\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"267300\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"5857"}
{"type":"Disease","public_definition":"Individuals with hereditary distal renal tubular acidosis (dRTA) typically present in infancy with failure to thrive, although later presentations can occur, especially in individuals with autosomal dominant SLC4A1-dRTA. Initial clinical manifestations can also include emesis, polyuria, polydipsia, constipation, diarrhea, decreased appetite, and episodes of dehydration. Electrolyte manifestations include hyperchloremic non-anion gap metabolic acidosis and hypokalemia. Renal complications of dRTA include nephrocalcinosis, nephrolithiasis, medullary cysts, and impaired renal function. Additional manifestations include bone demineralization (rickets, osteomalacia), growth deficiency, sensorineural hearing loss (in ATP6V0A4-, ATP6V1B1-, and FOXI1-dRTA), and hereditary hemolytic anemia (in some individuals with SLC4A1-dRTA).","keywords":[],"name":"Renal tubular acidosis, distal, with hemolytic anemia","alternate_names":["RENAL TUBULAR ACIDOSIS, DISTAL, 4, WITH HEMOLYTIC ANEMIA"],"attribute_content":[],"alternate_symbols":[],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"31600044\",\"@Source\":\"PubMed\"},{\"$\":\"NBK547595\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C1969038","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0012700\"}","{\"db\":\"OMIM\",\"id\":\"611590\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"93610\"}","{\"db\":\"OMIM\",\"id\":\"109270.0021\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RENAL TUBULAR ACIDOSIS, DISTAL, 4, WITH HEMOLYTIC ANEMIA\"}","{\"db\":\"OMIM\",\"id\":\"109270.0022\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RENAL TUBULAR ACIDOSIS, DISTAL, 4, WITH HEMOLYTIC ANEMIA\"}","{\"db\":\"OMIM\",\"id\":\"109270.0027\",\"type\":\"Allelic variant\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RENAL TUBULAR ACIDOSIS, DISTAL, 4, WITH HEMOLYTIC ANEMIA\"}","{\"db\":\"OMIM\",\"id\":\"611590\",\"type\":\"MIM\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"RENAL TUBULAR ACIDOSIS, DISTAL, 4, WITH HEMOLYTIC ANEMIA\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Renal+tubular+acidosis%2C+distal%2C+with+hemolytic+anemia/9218\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK547595\",\"ref_field\":\"public_definition\"}"],"id":"5856"}
{"type":"Disease","public_definition":"Individuals with hereditary distal renal tubular acidosis (dRTA) typically present in infancy with failure to thrive, although later presentations can occur, especially in individuals with autosomal dominant SLC4A1-dRTA. Initial clinical manifestations can also include emesis, polyuria, polydipsia, constipation, diarrhea, decreased appetite, and episodes of dehydration. Electrolyte manifestations include hyperchloremic non-anion gap metabolic acidosis and hypokalemia. Renal complications of dRTA include nephrocalcinosis, nephrolithiasis, medullary cysts, and impaired renal function. Additional manifestations include bone demineralization (rickets, osteomalacia), growth deficiency, sensorineural hearing loss (in ATP6V0A4-, ATP6V1B1-, and FOXI1-dRTA), and hereditary hemolytic anemia (in some individuals with SLC4A1-dRTA).","keywords":[],"name":"RENAL TUBULAR ACIDOSIS, DISTAL, 3, WITH OR WITHOUT HEARING LOSS, AUTOSOMAL RECESSIVE","alternate_names":["RTA, distal, autosomal recessive","Renal tubular acidosis, autosomal recessive with preserved hearing","Renal tubular acidosis, distal, autosomal recessive"],"attribute_content":[],"alternate_symbols":["RTADR"],"content":"{\"Citation\":{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"31600044\",\"@Source\":\"PubMed\"},{\"$\":\"NBK547595\",\"@Source\":\"BookShelf\"}]}}","medgen_id":"C1864498","symbol":"DRTA3","xrefs":["{\"db\":\"OMIM\",\"id\":\"602722\",\"type\":\"MIM\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Renal+tubular+acidosis%2C+distal%2C+autosomal+recessive/6215\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Renal tubular acidosis, distal, autosomal recessive\"}","{\"db\":\"OMIM\",\"id\":\"602722\",\"type\":\"MIM\",\"ref_field\":\"alternate_symbols\",\"ref_field_element\":\"RTADR\"}","{\"db\":\"OMIM\",\"id\":\"602722\",\"type\":\"MIM\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK547595\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"602722\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"4322"}
{"type":"Disease","public_definition":"Hereditary neuropathy with liability to pressure palsies (HNPP) is characterized by recurrent acute sensory and motor neuropathy in a single or multiple nerves. The most common initial manifestation is the acute onset of a non-painful focal sensory and motor neuropathy in a single nerve (mononeuropathy). The first attack usually occurs in the second or third decade but earlier onset is possible. Neuropathic pain is increasingly recognized as a common manifestation. Recovery from acute neuropathy is usually complete; when recovery is not complete, the resulting disability is mild. Some affected individuals also demonstrate a mild-to-moderate peripheral neuropathy.","gard_id":"5221","keywords":[],"name":"Hereditary liability to pressure palsies","alternate_names":["Hereditary Neuropathy with Liability to Pressure Palsies","Hereditary neuropathy with liability to pressure palsy","Polyneuropathy, familial recurrent","Tomaculous neuropathy"],"attribute_content":[],"alternate_symbols":[],"content":"{\"Citation\":[{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301566\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1392\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"EuroGenetest, 2010\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"2987431\",\"@Source\":\"pmc\"}}]}","medgen_id":"C0393814","symbol":"HNPP","xrefs":["{\"db\":\"MONDO\",\"id\":\"MONDO:0008087\"}","{\"db\":\"OMIM\",\"id\":\"162500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"640\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1392\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Hereditary Neuropathy with Liability to Pressure Palsies\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"5221\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Hereditary+neuropathy+with+liability+to+pressure+palsy/3369\",\"ref_field\":\"name\"}","{\"db\":\"SNOMED CT\",\"id\":\"230558006\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1392\",\"ref_field\":\"public_definition\"}","{\"db\":\"OMIM\",\"id\":\"162500\",\"type\":\"MIM\",\"ref_field\":\"symbol\"}"],"id":"3094"}
{"type":"Disease","disease_mechanism":"Fabry disease is due to inactivating mutations in the X-linked GLA gene resulting in deficiency of the enzyme Alpha Galactosidase-A.","public_definition":"Fabry disease results from deficient activity of the enzyme alpha-galactosidase A (a-Gal A) and progressive lysosomal deposition of globotriaosylceramide (GL-3) in cells throughout the body. The classic form, occurring in males with less than 1% a-Gal A enzyme activity, usually has its onset in childhood or adolescence with periodic crises of severe pain in the extremities (acroparesthesia), the appearance of vascular cutaneous lesions (angiokeratomas), sweating abnormalities (anhidrosis, hypohidrosis, and rarely hyperhidrosis), characteristic corneal and lenticular opacities, and proteinuria. Gradual deterioration of renal function to end-stage renal disease (ESRD) usually occurs in men in the third to fifth decade. In middle age, most males successfully treated for ESRD develop cardiac and/or cerebrovascular disease, a major cause of morbidity and mortality. Heterozygous females typically have milder symptoms at a later age of onset than males. Rarely, they may be relatively asymptomatic throughout a normal life span or may have symptoms as severe as those observed in males with the classic phenotype. In contrast, males with greater than 1% a-Gal A activity may have: (1) a cardiac variant phenotype that usually presents in the sixth to eighth decade with left ventricular hypertrophy, cardiomyopathy and arrhythmia, and proteinuria, but without ESRD; or (2) a renal variant phenotype, associated with ESRD but without the skin lesions or pain; or (3) cerebrovascular disease presenting as stroke or transient ischemic attack.","gard_id":"6400","keywords":[],"name":"Fabry disease","alternate_names":["Alpha-galactosidase A deficiency","Anderson-Fabry disease","Angiokeratoma corporis diffusum","Angiokeratoma, diffuse","Ceramide trihexosidase deficiency","Ceramide trihexosidosis","Fabry syndrome","Fabry's disease","GLA deficiency","Hereditary dystopic lipidosis"],"attribute_content":["{\"Attribute\":{\"$\":\"loss of function\",\"@Type\":\"disease mechanism\",\"@integerValue\":\"273\"},\"XRef\":[{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000514924\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520414\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528516\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000551442\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000246735\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000260631\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520063\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000505068\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000507480\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000507942\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000522527\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000568367\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000591289\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000520447\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528528\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000552214\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000556520\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000558532\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000325415\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000512526\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528276\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528500\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000528536\"},{\"@DB\":\"Genetic Testing Registry (GTR)\",\"@ID\":\"GTR000556501\"}]}"],"alternate_symbols":[],"content":"{\"Citation\":[{\"@Type\":\"general\",\"ID\":{\"$\":\"3009617\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"GeneReviews\",\"@Type\":\"review\",\"ID\":[{\"$\":\"20301469\",\"@Source\":\"PubMed\"},{\"$\":\"NBK1292\",\"@Source\":\"BookShelf\"}]},{\"@Abbrev\":\"HFSA, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"20610207\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2002\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"12735292\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Eng et al., 2006\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"16980809\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"Salviati et al, 2010\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"2869001\",\"@Source\":\"pmc\"}},{\"@Abbrev\":\"EuroGentest, 2011\",\"@Type\":\"Translational/Evidence-based\",\"ID\":{\"$\":\"21934708\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2013\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"23788249\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"AHA/ASA, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25355838\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"NSGC, 2013\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"23860966\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ESC, 2014\",\"@Type\":\"practice guideline\",\"ID\":{\"$\":\"25173338\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2015\",\"@Type\":\"Recommendation\",\"ID\":{\"$\":\"25356965\",\"@Source\":\"PubMed\"}},{\"@Abbrev\":\"ACMG, 2016\",\"@Type\":\"Recommendation\",\"ID\":[{\"$\":\"27854360\",\"@Source\":\"PubMed\"},{\"$\":\"10.1038/gim.2016.190\",\"@Source\":\"DOI\"}]}]}","medgen_id":"C0002986","xrefs":["{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"type\":\"primary\"}","{\"db\":\"MONDO\",\"id\":\"MONDO:0010526\"}","{\"db\":\"OMIM\",\"id\":\"301500\",\"type\":\"MIM\"}","{\"db\":\"Orphanet\",\"id\":\"324\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Angiokeratoma corporis diffusum\"}","{\"db\":\"Human Phenotype Ontology\",\"id\":\"HP:0001071\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry syndrome\"}","{\"db\":\"Genetic Alliance\",\"id\":\"Fabry+Disease/2690\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry's disease\"}","{\"db\":\"SNOMED CT\",\"id\":\"16652001\",\"ref_field\":\"alternate_names\",\"ref_field_element\":\"Fabry's disease\"}","{\"db\":\"Genetic Testing Registry (GTR)\",\"id\":\"GTR000500007\",\"ref_field\":\"disease_mechanism\"}","{\"db\":\"Office of Rare Diseases\",\"id\":\"6400\",\"ref_field\":\"gard_id\"}","{\"db\":\"Genetics Home Reference\",\"id\":\"fabry-disease\",\"ref_field\":\"name\"}","{\"db\":\"GeneReviews\",\"id\":\"NBK1292\",\"ref_field\":\"public_definition\"}"],"id":"1790"}
